Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 10/20 | 0.39 |
| ▸ | EED | O75530 | 9/20 | 0.39 |
| ▸ | RBBP4 | Q09028 | 9/20 | 0.39 |
| ▸ | SUZ12 | Q15022 | 9/20 | 0.39 |
| ▸ | AEBP2 | Q6ZN18 | 9/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.31 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25514525 | 0.92 | CDK5 (0.38) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL22872249 | 0.91 | EZH2 (0.39) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21342285 | 0.89 | EZH2 (0.41) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL22817667 | 0.87 | CDK5 (0.39) | EZH2CDK5CDK5R1GSK3BJAK3 | |
| SCHEMBL22872247 | 0.85 | EED (0.35) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21342276 | 0.83 | CDK5 (0.42) | EZH2CDK5CDK5R1GSK3BJAK3 | |
| SCHEMBL25514539 | 0.83 | RET (0.35) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21341798 | 0.81 | EZH2 (0.64) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL25514520 | 0.80 | EZH2 (0.43) | EZH2 | |
| SCHEMBL21342281 | 0.79 | EZH2 (0.41) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | HAIHE BIOPHARMA CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| EP-3763712-B1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-3763712-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
| WO-2019170063-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661421-B2 | Indolizine compounds, preparation method and use thereof | EZH1, EZH2, IKZF3 | EZH2 2/4885EED 12/4885RBBP4 1315/4885 |
| US-20200399270-A1 | INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | EZH1, EZH2, IKZF3 | EZH2 2/4885EED 12/4885RBBP4 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.